This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio
by Zacks Equity Research
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.
MMSINegative Net Change CORNegative Net Change ITGRNegative Net Change HIMSNegative Net Change
medical medical-devices
FONR Stock Rises Following Q3 Earnings on Higher Net Income
by Zacks Equity Research
FONAR Corporation's Q3 fiscal 2025 results show higher net income and revenue growth, driven by record MRI scan volumes and strong performance of its HMCA unit.
FONRPositive Net Change
earnings medical medical-devices
4 Medical Product Stocks to Watch From a Challenging Industry
by Indrajit Bandyopadhyay
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
PODDNegative Net Change MGNXNegative Net Change CLRBPositive Net Change ALURNegative Net Change
medical medical-devices
AST Business Growth & Strategic Acquisitions Support STERIS Stock
by Zacks Equity Research
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
PBHNegative Net Change STENegative Net Change PAHCNegative Net Change HIMSNegative Net Change
medical medical-devices
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
by Zacks Equity Research
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
ANGOPositive Net Change BAXNegative Net Change CVSNegative Net Change ITGRNegative Net Change
medical medical-devices
MainStreet Bank (MNSB) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MNSBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Karooooo Ltd. (KARO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KAROPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
ANGOPositive Net Change CVSNegative Net Change QDELNegative Net Change ITGRNegative Net Change
medical medical-devices
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
by Zacks Equity Research
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
DGXNegative Net Change PBHNegative Net Change PAHCNegative Net Change INSPNegative Net Change
medical medical-devices
Here's Why You Should Retain Glaukos Stock in Your Portfolio
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
CVSNegative Net Change CORNegative Net Change GKOSNegative Net Change WGSNegative Net Change
medical medical-devices
Vaso Stock Slips Post Q1 Earnings Despite Record Revenue Growth
by Zacks Equity Research
VASO's first-quarter 2025 revenues hit a record high, but a narrowed net loss and muted stock reaction highlight investor caution despite solid segment growth.
VASOPositive Net Change
earnings medical medical-devices
First Western (MYFW) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MYFWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Rivian Automotive (RIVN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
RIVNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Pagaya Technologies Ltd. (PGY) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PGYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
by Zacks Equity Research
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
ANGOPositive Net Change SYKNegative Net Change CVSNegative Net Change ITGRNegative Net Change
medical medical-devices
Should You Continue to Hold Charles River Stock in Your Portfolio?
by Zacks Equity Research
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
CRLNegative Net Change PBHNegative Net Change PAHCNegative Net Change INSPNegative Net Change
medical medical-devices
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
by Zacks Equity Research
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
ILMNNegative Net Change PBHNegative Net Change PAHCNegative Net Change HIMSNegative Net Change
medical medical-devices
Cooper Companies Q2 Earnings Likely to Reflect Seasonal Trends
by Zacks Equity Research
COO's fiscal second-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
LHNegative Net Change MCKNegative Net Change XRAYNegative Net Change COONegative Net Change
medical medical-devices
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
by Zacks Equity Research
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
ANGOPositive Net Change BDXNegative Net Change CVSNegative Net Change ITGRNegative Net Change
medical medical-devices
ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
BSXNegative Net Change CAHNegative Net Change ZBHNegative Net Change HIMSNegative Net Change
medical medical-devices
Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs
by Zacks Equity Research
Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.
ABTNegative Net Change BSXNegative Net Change CAHNegative Net Change HIMSNegative Net Change
medical medical-devices
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
by Zacks Equity Research
Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.
CVSNegative Net Change CORNegative Net Change HIMSNegative Net Change WGSNegative Net Change
medical medical-devices
MCK Stock Gains More Than 4% Following Strong Q4: Should You Buy Now?
by Indrajit Bandyopadhyay
McKesson's strong fundamentals are likely to keep it ahead of the competition. Should investors add it to their portfolio now?
CAHNegative Net Change MCKNegative Net Change CORNegative Net Change
medical medical-devices
Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?
by Debanjana Dey
HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.
ABTNegative Net Change TDOCNegative Net Change HIMSNegative Net Change
medical medical-devices
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
ECLNegative Net Change ANGOPositive Net Change CVSNegative Net Change ITGRNegative Net Change
medical medical-devices